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Abstract 36 
 37 
 Magnetic Resonance Image-guided Focused Ultrasound (MRgFUS) has been used to 38 
achieve transient BBB opening without tissue injury. Delivery of a targeted ultrasonic wave 39 
causes an interaction between administered microbubbles and the capillary bed resulting in 40 
enhanced vessel permeability. The use of MRgFUS in the brainstem has not previously been 41 
shown but could provide value in the treatment of tumours such as Diffuse Intrinsic Pontine 42 
Glioma (DIPG) where the intact BBB has contributed to the limited success of chemotherapy. 43 
Our primary objective was to determine whether the use of MRgFUS in this eloquent brain 44 
region could be performed without histological injury and functional deficits. Our secondary 45 
objective was to select an effective chemotherapeutic against patient derived DIPG cell lines 46 
and demonstrate enhanced brainstem delivery when combined with MRgFUS in vivo. 47 
 Female Sprague Dawley rats were randomised to one of four groups: 1) Microbubble 48 
administration but no MRgFUS treatment; 2) MRgFUS only; 3) MRgFUS + microbubbles; 49 
and 4) MRgFUS + microbubbles + cisplatin. Physiological assessment was performed by 50 
monitoring of heart and respiratory rates. Motor function and co-ordination were evaluated by 51 
Rotarod and grip strength testing. Histological analysis for haemorrhage (H&E), neuronal 52 
nuclei (NeuN) and apoptosis (cleaved Caspase-3) was also performed. A drug screen of eight 53 
chemotherapy agents was conducted in three patient-derived DIPG cell lines (SU-DIPG IV, 54 
SU-DIPG XIII and SU-DIPG XVII). Doxorubicin was identified as an effective agent. 55 
NOD/SCID/GAMMA (NSG) mice were subsequently administered with 5mg/kg of 56 
intravenous doxorubicin at the time of one of the following: 1) Microbubbles but no MRgFUS; 57 
2) MRgFUS only; 3) MRgFUS + microbubbles and 4) no intervention. Brain specimens were 58 
extracted at 2 hours and doxorubicin quantification was conducted using liquid 59 
chromatography mass spectrometry (LC/MS).  60 
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 BBB opening was confirmed by contrast enhancement on T1-weighted MR imaging 61 
and positive Evans blue staining of the brainstem. Normal cardiorespiratory parameters were 62 
preserved. Grip strength and Rotarod testing demonstrating no decline in performance across 63 
all groups. Histological analysis showed no evidence of haemorrhage, neuronal loss or 64 
increased apoptosis. 65 
 Doxorubicin demonstrated cytotoxicity against all three cell lines and is known to have 66 
poor BBB permeability. Quantities measured in the brainstem of NSG mice were highest in 67 
the group receiving MRgFUS and microbubbles (431.5 ng/g). This was significantly higher 68 
than in mice who received no intervention (7.6 ng/g).  69 
 Our data demonstrates both the preservation of histological and functional integrity of 70 
the brainstem following MRgFUS for BBB opening and the ability to significantly enhance 71 
drug delivery to the region, giving promise to the treatment of brainstem-specific conditions.  72 
Keywords: Focused Ultrasound, Brainstem, Feasibility, Drug Delivery 73 
Introduction 74 
 The human brainstem is perhaps the most eloquent brain region housing crucial 75 
regulatory centres of wakefulness and cardiorespiratory control in addition to cranial nerve 76 
nuclei and neural tracts relaying motor and sensory information between the brain, spinal cord 77 
and cerebellum. Tumours arising in the region are therefore difficult to treat. Those with well 78 
demarcated borders can be surgically resected but despite intra-operative monitoring of these 79 
crucial functions, significant morbidity can arise [1]. The most commonly occurring brainstem 80 
tumour however, displays a diffuse growth pattern and is therefore not amenable to surgical 81 
resection. Diffuse Intrinsic Pontine Glioma (DIPG) results in a near 100% fatality rate within 82 
2 years of diagnosis [2] and is the leading cause of brain tumour deaths in children [3].  83 
 Clinical trials assessing both single agent and combination chemotherapies have failed 84 
to improve the survival of patients with DIPG [4,5]. A key factor believed to be limiting the 85 
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efficacy of these agents is an intact blood brain barrier (BBB) [6]. As such, the current standard 86 
of care consists of focal radiation therapy to the pons, which provides a transient improvement 87 
in symptoms but limited survival benefit.  88 
The increased availability of biopsy and post-mortem specimens has enabled molecular 89 
profiling of DIPG demonstrating characteristic molecular alterations including epigenetic 90 
dysregulation as a key driver of tumorigenesis. Following whole genome and exome 91 
sequencing of patient samples, it was identified that 70-84% of DIPGs harbour a point mutation 92 
in the histone variants H3.1 and H3.3 [7-9]. This somatic gain of function mutation results in 93 
a lysine 27 to methionine substitution (p.Lys27Met, K27M) and enhanced gene transcription 94 
[10]. In addition, the majority of H3K27M mutants are associated with aberrations within the 95 
TP53 pathway and/or growth factor pathways in brain development including ACVR1/ALK2, 96 
FGFR1, PI3KR1 and PDGFRA [11-14]. These findings have led to the advancement of pre-97 
clinical models as well as new therapeutics. Rather promisingly, the histone deacetylase 98 
(HDAC) inhibitor, Panobinostat has demonstrated pre-clincial efficacy and is currently in 99 
Phase 1 trial (PBTC-047) [15]. 100 
These newer molecularly targeted therapies still face the challenge of achieving 101 
sufficient BBB penetration to result in clinically significant survival. MRI guided focused 102 
ultrasound (MRgFUS) provides a non-invasive means of focally disrupting the BBB. The 103 
technique uses low frequency ultrasound waves in combination with intravenously 104 
DGPLQLVWHUHGPLFUREXEEOHVȝ%s) to transiently open the BBB without tissue injury [16-18]. 105 
:KHQFLUFXODWLQJȝ%s encounter focused ultrasound (FUS) energy, they expand and contract 106 
in a process known as stable cavitation, exerting a mechanical force on the blood vessel wall 107 
causing rearrangement of tight junction proteins and increased active transport [19,20]. This 108 
effect is transitory, lasting between 4-6 hours [21,22]. Although microbubbles are 109 
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commercially approved as ultrasound contrast agents, it is important to highlight that their use 110 
in conjunction with focused ultrasound for BBB disruption is currently experimental. 111 
The integration of magnetic resonance image (MRI) guidance allows targeting of 112 
specific regions thereby preserving the integrity of the BBB elsewhere. MRgFUS has been 113 
shown to concentrate chemotherapeutics and macromolecules in targeted brain tissue as well 114 
as tumours with significant treatment effect [23-26]. Furthermore, the technique has been 115 
clinically translated with the design of a spherical, phased array, multi-element transducer 116 
helmet that enables ultrasound waves to penetrate the human calvarium [27], (ExAblate low 117 
frequency system, InSightec). 118 
 MRgFUS disruption of the BBB in the brainstem has not been studied to date. In this 119 
study, our primary objective was to determine the feasibility and safety of BBB disruption in 120 
the brainstem using MRgFUS in a rodent model. Our secondary objective was to identify an 121 
effective conventional chemotherapy agent against in vitro DIPG cell lines and to then 122 
determine the extent of enhanced brainstem delivery when combined with MRgFUS in vivo. 123 
Materials and Methods 124 
Animals 125 
For experiments pertaining to the safety of MRgFUS in the brainstem, female Sprague 126 
Dawley rats (Jackson Laboratory) were used, weighing 150 ± 250g at the start of each 127 
experiment. For experiments assessing Doxorubicin delivery to the brainstem, female 128 
NOD/SCID/GAMMA (NSG) mice (20 ± 25g, Jackson Laboratory) were used. All animals 129 
were housed at constant temperature (23 ± 1°C) and relative humidity (60 ± 5%) with free 130 
access to food and water and a fixed 12-h light/dark cycle.  131 
The use of animals and all animal procedures was approved by the Animal Care 132 
Committee at Sunnybrook Health Sciences Centre. All protocols used were in accordance with 133 
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the guidelines established by the Canadian Council on animal care and the Animals for 134 
Research Act of Ontario, Canada. 135 
 136 
Magnetic Resonance guided Focused Ultrasound of the Brainstem: 137 
Sprague Dawley Rats 138 
 Forty-two female Sprague Dawley rats (weight 150 ± 250g) were anaesthetised using 139 
inhaled isofluorane anaesthesia in an animal chamber prior to repositioning in a nose-cone. 140 
Hair over the dorsal aspect of the skull was shaved and further removed with depilatory cream. 141 
A 22g angio-catheter was inserted into the tail vein. The animal was placed and secured in a 142 
supine position, on a mount designed for targeted focused ultrasound delivery. Registration of 143 
WKHDQLPDO¶VSRVLWLRQZLWKLQWKHPRXQWZDVFRQGXFWHGZLWKD705,VFDQQHU%LR6SLQ144 
Bruker, Billerica, Mass). The exposed scalp was positioned on the water pack portion of the 145 
mount with ultrasound gel used between the 2 surfaces to achieve acoustic wave coupling. 146 
Initial T2 and T1 weighted axial and sagittal images were performed and used to set right and 147 
left sided brainstem targets. Following imaging and registration, the mount and attached animal 148 
were returned to the focused ultrasound system. The water pack portion of the mount was 149 
positioned to overlie a chamber of degassed, deionized water containing the transducer [28]. 150 
For physiological monitoring, an MRI compatible foot sensor of the MouseOx Plus 151 
physiological monitor (Starr Life Sciences Corp, Oakmont, USA) was attached to the left hind 152 
paw of the rat. Signal confirmation was achieved and physiological monitoring and recording 153 
of heart and respiratory rate was initiated. Duration of monitoring extended from at least 4 154 
minutes prior to initial right sided brainstem sonication and completed at least 4 minutes after 155 
left sided brainstem sonication. The timing of interventions was documented so as to later cross 156 
reference with the monitoring data. Data extracted was plotted and graphed using Graphpad 157 
Prism version 7 (California, USA).   158 
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An in-house-built three-axis focused ultrasound system was used. Ultrasound was 159 
generated using a 1.68MHz spherically-focused transducer (radius of curvature = 60mm, 160 
external diameter = 75mm, focal number 0.8). The transducer was driven by a function 161 
generator (33220A; Agilent Technologies, Santa Clara, CA) and a radiofrequency amplifier 162 
(NP2519; NP Technology, Newbury Park, CA). Each transcranial sonication consisted of 10-163 
millisecond bursts at a 1-Hz pulse repetition frequency for a total of 2 minutes. Microbubbles 164 
(PBs) (Definity® Lantheus Medical Imaging, Inc., N. Billerica, MA, U.S.A) were diluted 1:10 165 
in normal saline and administered intravenously (0.02mL/kg) at the onset of sonication. 166 
Microbubble emissions were detected during sonication by a custom built polyvinylidene 167 
difluoride hydrophone [29] connected to a scope card located in the controlling PC. Pressure 168 
amplitude was incremented after each burst (starting pressure 0.25, pressure increments of 169 
0.025) until sub or ultraharmonic emissions were detected in the fast fourier transform, (FFT) 170 
of the captured hydrophone signal by the PC. The remainder of the sonication proceeded at 171 
50% of this threshold pressure amplitude. This sonication protocol has been devised to ensure 172 
effective and replicable BBB opening without tissue injury [30].  173 
 A region consisting of a 4-point overlapping grid was treated in the right side of the 174 
pons and then repeated on the left side of the pons (Fig. 1A). The same dose of PBs was injected 175 
at the onset of the left sided sonication. Hence, the total PB dose delivered was 2 x 20uLkg. It 176 
should be noted that this is twice the clinically advised maximum dose of Definity 177 
microbubbles as an ultrasound contrast agent.  The two regions were sonicated at least five 178 
minutes apart to allow clearance of PBs from the initial injection (microbubble half-OLIH§-7 179 
minutes in Sprague Dawley rats)  [31] Rodents allocated to the PB control group received the 180 
same intravenous doses of PBs and gadolinium contrast but not the delivery of focused 181 
ultrasound. They were however positioned in the FUS mount for the same duration of time as 182 
WKHWUHDWHGDQLPDOV5DWVDOORFDWHGWRWKH³MRg)86´FRQWUROJURXSGLGQRWUHFHLYHWKHGRVHV183 
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of PBs but focused ultrasound and gadolinium contrast were administered at consistent time 184 
points as in the treated groups. Pre- and post-procedure imaging sequences were the same 185 
across all groups. 5DWV UDQGRPLVHG WR WKH ³MRg)86  ȝ%  &LVSODWLQ´ JURXS UHFHLYHG DQ186 
intravenous bolus dose of cisplatin (1.5 mg/kg) during the first (right sided) sonication 187 
delivered.  188 
  189 
NSG Mice 190 
Sixteen female NSG mice (20 ± 25g) were anaesthetised and prepared for MRgFUS 191 
delivery as above. A smaller 26 G catheter was used for tail vein catheterisation and a single 192 
4-point overlapping grid was treated in the centre of the pons. The smaller cross-sectional area 193 
of the brainstem in mice did not necessitate an 8-point treatment regime to achieve coverage. 194 
All mice were intravenously administered 5mg/kg of Doxorubicin (Cat. No. S1208, 195 
Selleckchem) at the time of MRgFUS delivery, immediately following the intravenous 196 
administration of microbubbles. Five mice were randomly allocated to each group. Groups 197 
were; 1) ³1R LQWHUYHQWLRQ´± mice received no focused ultrasound intervention. Mice were 198 
placed on the focused ultrasound device for the same period of time and administered 199 
gadolinium contrast at the same dose and time points as mice receiving interventions 2) 200 
³05J)86´ ± control group receiving focused ultrasound delivery without intravenously 201 
administered microbubbles, 3) PB ± control group receiving PBs without focused ultrasound 202 
HQHUJ\DQG³05J)86P%´± treatment group receiving both focused ultrasound energy 203 
and intravenously administered PBs.  204 
 205 
Assessment of BBB Disruption: 206 
Magnetic Resonance Imaging: 207 
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Contrast enhanced (0.1ml/kg Gadovist; Bayer HealthCare Pharmaceuticals, Inc. 208 
Leverkusen, Germany) T1 weighted imaging was used to assess BBB disruption after focused 209 
ultrasound delivery. The contrast agent was delivered after the left sided brainstem sonication 210 
in rats and at the time of the single brainstem sonication in mice. This was four minutes prior 211 
to imaging.  Images were extracted using the MIPAV (Medical Image Processing, Analysis 212 
and Visualization) application.  213 
Evans Blue administration:  214 
 A 4% Evans Blue dye was intravenously injected (4ml/kg) into a cohort of rats (n=5 215 
IRUHDFKJURXS³05J)86´³ȝ%´DQG³05J)86ȝ%´DQGQ IRUWKH³&RQWURO´ group). 216 
following the post procedure contrast enhanced MR imaging. Control rats received no 217 
intervention. Animals were maintained under anaesthesia using intramuscularly injected 218 
ketamine (100mg/ml Narketan; Vetoquinol, Toronto, at a dose of 100mg/kg) and xylazine 219 
(20mg/ml Rompun; Sigma-Aldrich, Toronto, 10mg/kg dose). Animals were euthanised at one 220 
hour after Evans Blue administration. They were deeply anaesthetised and transcardially 221 
perfused with 4% paraformaldehyde. Sectioning through the level of the pons was performed 222 
and images were taken using a dissecting microscope (Olympus SZX16).  223 
 224 
Assessment of Motor Function: 225 
Rotarod Testing: 226 
Rats were briefly pre-trained on an automated 4 lane rotarod unit (Rota Rod RS, Letica 227 
Scientific Instruments, Panlab Harvard Apparatus) initially on a fixed speed setting. An 228 
accelerating protocol was then used whereby rats were placed on a rod that accelerated 229 
smoothly from 4 to 40rpm over a period of 1 minute. The length of time that each animal was 230 
able to stay on the rod was recorded as the latency to fall, registered automatically by a trip 231 
switch under the floor of each rotating drum. Five successive recordings were taken for each 232 
rat (with 5-minute rest intervals between each trial) on five consecutive mornings one week 233 
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prior and one week post brainstem sonication. The rats were not labelled regarding their 234 
randomization group and thus the operator conducting post-procedure testing was blinded to 235 
the intervention. 236 
Grip Strength Testing: 237 
Rat forelimb grip strength was measured using an electronic digital force gauge grip-238 
strength meter with accompanying grid fixture (Bioseb Instruments, Pinellas Park, Florida, 239 
USA). Rats were placed onto the grid, allowing forelimbs to take grip. Rats were drawn back 240 
in a straight line away from the sensor until they eventually released their grip. The peak force 241 
JH[HUWHGE\WKHDQLPDO¶VJULSZDVUHFRUGHG(LJKWWULDOVZHre conducted (with 5-minute rest 242 
intervals between each trial), on three alternate days, one week prior to and one week post 243 
brainstem sonication. A single operator was used for all grip strength recordings to reduce 244 
operator variability and was also blinded to the intervention.  245 
 246 
Histologic Analysis: 247 
 Rats UDQGRPLVHGWRWKH³HDUO\´KLVWRORJ\JURXSQ SHUJURXSZHUHHXWKDQLVHG248 
KRXUVIROORZLQJWKHLUDOORFDWHGLQWHUYHQWLRQ7KH³ODWH´KLVWRORJ\JURXSQ SHUJURXSZHUH249 
euthanised on day 14 post intervention, allowing for post procedure grip strength and rotarod 250 
testing. These time points were chosen to maximise the potential of capturing apoptosis which 251 
could arise in either an acute or delayed fashion. Furthermore, assessment of neuronal number 252 
following MRgFUS has previously been measured at 8 days following intervention. [30]. A 253 
cohort (n = 5) of untreated rats were sacrificed to provide negative control tissue. Brains were 254 
extracted and stored in 10% neutral buffered formalin. Fixed tissues were dehydrated and 255 
embedded in paraffin. Brains were axially sectioned in three regions of the brainstem.  Five 256 
ȝPWKLFND[LDOVHFWLRQVZHUHFXWDQGPRXQWHGRQWRVOLGHVDQGdeparaffinised using xylene and 257 
hydrated with decreasing concentrations of ethanol. Haematoxylin and eosin (H&E) staining 258 
was used to determine the histopathological features. H&E stained sections were independently 259 
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reviewed by a veterinary pathologist who was blinded to the sample labels. Tissues were 260 
immunostained for NeuN (Abcam,1:1000) and cleaved caspase 3 (cell signalling, 1:100) to 261 
evaluate neuronal integrity and apoptosis respectively. Sections were imaged using a 3D 262 
Histech Panoramic 250 slide scanner. Quantification of staining was performed using the 263 
Quantification Centre (QC) feature of the Panoramic Viewer software application (3DHistech, 264 
Budapest, Hungary) which uses a colorimetric algorithm to calculate the percentage of positive 265 
pixels over a designated tissue area, defined as relative mask area (rMA). A protocol was 266 
FUHDWHGLQWKH³KLVWRORJ\´VXE-feature and the brainstem was outlined in each sample as the 267 
region of interest.  268 
 269 
Drug Screening 270 
Cell lines described here were obtained through a Material Transfer Agreement with the 271 
originating institution, Stanford University.  Cell lines were validated by DNA fingerprinting 272 
using short tandem repeat analysis. Eight chemotherapy agents were selected from prior 273 
published in vitro efficacy in either DIPG or paediatric high-grade glioma cell lines [32].. The 274 
HP-300 Digital Drug Dispenser was used to enable automated and accurate dispensing of drugs 275 
in a 384 well format. For each compound, a twelve-point dose range, customised from 276 
previously published IC50 data (Fig. 7A), was dispensed in a scrambled format to reduce 277 
plating artefacts. Each DIPG cell line (SU-DIPG IV, SU-DIPG XIII and SU-DIPG XVII) was 278 
plated into a 384 well plate (containing the chemotherapy agents) using the Thermo Multidrop 279 
(ThermoFischer Scientific, Canada) at 4000 cells per well. Viability was assessed at day 5. 280 
Alamar Blue Cell Viability Reagent (ThermoFischer Scientific, Canada) was added to each 281 
well, again using the Thermo Multidrop, and incubated for 3 hr. Optical absorbance values at 282 
550nm-590nm from each well were measured using a plate reader (Spectra Max Gemini EM). 283 
Percent cell viability at each drug concentration was determined relative to vehicle control 284 
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(DMSO) and IC50 values were calculated in excel using the XLfit Plugin (IDBS) with the 285 
Boltzmann sigmoidal curve fitting algorithm. Three replications were conducted for each cell 286 
line.  287 
 288 
Liquid Chromatography-Tandem Mass Spectrometry (LC/MS/MS) 289 
NSG mice were anaesthetised two hours following intravenous Doxorubicin delivery 290 
using intramuscularly injected ketamine (100mg/ml Narketan; Vetoquinol, Toronto, at a dose 291 
of 100mg/kg) and xylazine (20mg/ml Rompun; Sigma-Aldrich, Toronto, 10mg/kg dose). Once 292 
deeply anaesthetised, mice were transcardially perfused with 0.9% sodium chloride solution 293 
for seven minutes and then euthanised. Brains were extracted and divided into the cerebrum, 294 
cerebellum and brainstem, placed in individually labelled cryotubes and snap frozen in liquid 295 
nitrogen. Samples were stored at -80q C until analysis was conducted.  296 
Samples were analysed by LC/MS/MS at the Analytical Facility for Bioactive 297 
Molecules (The Hospital for Sick Children, Toronto, Canada). Sample preparation was carried 298 
out under reduced light conditions and cold temperature (4°C) using only plasticware.  299 
Working solutions of daunorucin (0.2 µg/mL) and doxorubicin standard curve (nine points 300 
prepared by serial dilutions, ranging from 5 to 2500 ng/mL) were prepared fresh from 301 
0.1mg/mL stock solutions kept at -80qC. 302 
Frozen samples were weighed and transferred into Precellys homogenization tubes 303 
containing ceramic beads (Bertin Technologies, Rockville, Washington DC). Extraction 304 
solvent consisting of 60% acetonitrile and 40% 0.05 M ammonium acetate, pH 3.50 (v/v) was 305 
added to achieve 10mg/mL and homogenised using a Precellys 24 high-throughput 306 
homogenizer (Bertin Technologies, Rockville, Washington DC) - two 20 second bursts at 5500 307 
rpm with a 30 second pause. 100 PL of the homogenised suspension (corresponding to 10 mg 308 
tissue) was transferred into a set of 1.5 mL Eppendorf tubes. Ten PL of working daunorubicin 309 
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was added followed by 100 PL of extraction solvent. Samples were mixed by vortex, kept on 310 
ice for ten minutes and centrifuged at 20,000 g for fifteen minutes at 4°C. Supernatants were 311 
taken to dryness under N2 gas. Residues were reconstituted in 100 PL of MeOH/H2O (50/50) 312 
+ 0.1% formic acid, centrifuged at 20,000 g for ten minutes at 4°C and transferred into 200 PL 313 
plastic inserts for LC/MS/MS analysis.  314 
Doxorubicin and daunorubicin were measured by LC/MS/MS using a QTRAP 5500 315 
triple-quadruple mass spectrometer (Sciex: Framingham, Massachusetts, USA) in positive 316 
electrospray ionization mode by MRM data acquisition with an Agilent 1200 HPLC (Agilent 317 
Technologies: Santa Clara, California, USA). Chromatography was performed by automated 318 
injection of 3 µL on a Kinetex XB C18 column, 50 x 3 mm, 2.6 µm particle size (Phenomenex, 319 
Torrance, CA). The HPLC flow was maintained at 600 µL/minute with a gradient consisting 320 
of: A= Water + 0.1% Formic Acid and B = Acetonitrile + 0.1% Formic Acid. Total run time 321 
was 5 minutes. 322 
Quantification was performed on Analyst 1.6.1 software (ABSciex: Framingham, 323 
Massachusetts, USA) by plotting the sample peak area ratios (analyte peak area/internal 324 
standard peak area) of doxorubicin against a standard curve generated from various 325 
concentrations of doxorubicin from 0.01 ng to 10 ng, spiked with the same amount of 326 
daunorubicin used for the samples and extracted in the same conditions. The use of 327 
daunorubicin as an internal standard is due to its structural similarity to doxorubicin and 328 
therefore similar extraction recovery and chromatographic properties. [33,34]. 329 
 330 
Statistical Analysis  331 
Sprague Dawley Rats 332 
Rotarod and grip strength data were analysed using a two-way mixed multivariate 333 
DQDO\VLVRIYDULDQFH0$129$ZLWK7XNH\¶Vpost hoc test. Histology data was compared 334 
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using a three-way 0$129$ZLWK7XNH\¶VSRVW-hoc test. Significance was deemed an alpha 335 
level of P < 0.05 (*) or P< 0.01(**) with a 95% confidence interval.  336 
Physiological monitoring of heart and respiratory rate were analysed using a two-way 337 
multivariate mixed model analysis of variance. 338 
NSG Mice  339 
 Doxorubicin quantities between treatments and across brain regions (cerebrum, 340 
brainstem and cerebellum) by two-way mixed ANOVA. Significance levels were either P< 341 
0.05 (*), P < 0.01 (**) or P < 0.001(***) with a 95% confidence interval. A two-way mixed 342 
ANOVA was used to compare doxorubicin quantities across brain regions.  343 
 344 
Results  345 
MRgFUS Parameters for BBB Disruption: 346 
The average peak pressure amplitude reached across all sonications performed in rats 347 
was estimated to be 1.1 +/- 0.3 MPa and in mice was 0.71 +/- 0.15 MPa. The in situ pressures 348 
were estimated assuming a 55% transmission through the skull bone [35] and attenuation of 5 349 
Np/m/MHz [18]through 5 mm of brain tissue. The assumed transmission of 55% through the 350 
skull bone at this frequency may result in an over-estimation of the true in situ pressures as this 351 
figure was obtained from measurements recorded through a more rostral portion of rat parietal 352 
bone [35].  The more posterior trajectory of ultrasound in our study, through a caudal portion 353 
of the skull with both an increased degree of curvature and thickness, would be expected to 354 
result in a higher insertion loss. 355 
 356 
Confirmation of brainstem BBB opening:  357 
Sprague Dawley rats 358 
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Two methods were used to confirm BBB disruption in the brainstem, namely focal 359 
gadolinium (Gad) enhancement on post procedure T1-weighted MR imaging (Fig. 1) and 360 
Evans Blue staining of gross histological specimens (Fig. 2). Immediately following 361 
sonication, only rats which received concurrent intravenous injection of ȝ%s ³MRg)86ȝ%´362 
DQG ³MRg)86  ȝ%  &LV´ FOHDUO\ VKRZHG ORFDOLVHG *DG HQKDQFHPHQW LQ WKH EUDLQVWHP363 
indicating BBB disruption.  364 
 365 
 366 
 367 
Figure 1: Brainstem sonication schema used in Sprague Dawley rats. (Colour Figure) 368 
 369 
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370 
Figure 2: Evans Blue staining of rodent brainstem confirming BBB opening. (Colour 371 
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Figure) 372 
To further confirm our MRI observations, intravenous Evans Blue was delivered 373 
following sonication to demonstrate the extent of BBB disruption histologically. Blue staining 374 
was observed on the ventral surface of the brainstem, in and around the region of the pons (Fig. 375 
2G). On sectioning through the brainstem at the level of the pons, blue staining of both the 376 
brainstem and a portion of the ventral cerebellum was evident (Fig. 2H). The presence of dye 377 
LQWKHEUDLQVWHPZDVDJDLQRQO\VHHQLQWKH³MRg)86ȝ%´JURXSWKH³MRg)86ȝ%378 
&LV´JURXSZDVQRWWHVWHGDQGQRWLQHLWKHUWKH³MRg)86´ ³ȝ%´RU³FRQWURO´groups (Fig. 379 
2A-F).   380 
NSG Mice 381 
 Focal gadolinium enhancement on post-procedure T1 weighted imaging was used to 382 
confirm BBB disruption in NSG mice administered doxorubicin (Supplementary Fig. 3). As 383 
DERYH RQO\ PLFH LQ WKH ³05J)86  ȝ%´ FRKRUW GHPRQVWUDWHG EUDLQVWHP JDGROLQLXP384 
enhancement (Supplementary Fig. 3B) indicating successful BBB permeability in the region.  385 
 386 
Physiological monitoring of heart and respiratory rate during brainstem focused 387 
ultrasound delivery: 388 
Grey matter nuclei contained within the brainstem include the cardiovascular and 389 
medullary rhythmicity centres which together control the heart rate, blood pressure and 390 
respiratory rate. As such, tissue injury to this region has the potential to affect these vital 391 
functions. Once under anaesthesia, rats were recorded for 4 minutes to determine baseline vital 392 
signs and ensure stable signal detection. Monitoring was continued throughout MRgFUS and 393 
for a further 4 minutes after. The normal heart rate in rats varies from 250 - 450 beats per 394 
minute with a respiratory rate up to 85 beats per minute. Although variability and fluctuations 395 
are seen in both parameters, these were not concurrent with periods of focused ultrasound 396 
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delivery (Fig. 3 - pink bars) but rather occurred consistently throughout the period of 397 
monitoring. Statistical comparison was made of the mean heart rate and respiratory rate during 398 
and after MRgFUS delivery to that of baseline before intervention recordings and no significant 399 
difference was found (Fig. 4) Both parameters remained stable throughout the monitoring 400 
period with no persistent fluctuations from baseline or abrupt cessation of parameters. This was 401 
true for all animals across the different treatment groups (Fig. 3 & 4). 402 
 403 
 404 
 405 
Figure 3: Physiological monitoring of heart and respiratory rate. (Colour Figure) 406 
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407 
Figure 4: Comparison of (A) mean heart rate and (B) respiratory rate recordings 408 
of rats before, during and after the specified procedures. 409 
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Motor control and coordination following focused ultrasound delivery to the brainstem: 410 
 Both rotarod and grip strength data were compared pre- and post-MRgFUS delivery to 411 
the rat brainstem (Fig. 5). Comparison of post procedure performance with pre-procedure 412 
untreated performance provided an internal negative control. No statistically significant 413 
differences were identified in rotarod performance when comparing performance between 414 
groups. However, animals within each group demonstrated improved performance on post-415 
procedure testing which may be attributed to the expected improvement in performance by 416 
animals with repeated measurements. (Fig. 5A). These findings were also found in grip 417 
strength testing (Fig. 5B).  418 
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 419 
Figure 5: Comparison of rotarod and grip strength performance pre-and post-procedure. 420 
Histological assessment of brainstem tissue: 421 
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 Three levels of the rodent brainstem were assessed (Fig. 6A). Sections were stained 422 
with H&E for cell morphology, Caspase-3 for apoptosis and NeuN for neuronal number. These 423 
parameters were chosen as focused ultrasound could potentially cause tissue damage in the 424 
form of haemorrhage and tissue vacuolation, increased apoptosis and neuronal loss [30,36]. At 425 
both early (4 hours) and late (14 day) time points, H&E stained sections did not show evidence 426 
of tissue damage or haemorrhage in any of our groups when compared with untreated controls 427 
(Fig. 6B). This was independently verified by a veterinary pathologist who was blinded to the 428 
sample groupings. In addition, we did not note any significant differences in positive caspase 429 
3 for any groups compared to untreated controls (Fig. 7A & Supplementary Fig. 1).  430 
Similarly, there were no changes in neuronal number between groups, at all levels of the 431 
brainstem (Fig. 7B & Supplementary Fig. 2).  432 
 433 
Figure 6: Hematoxylin and eosin (H&E) staining of brainstem sections. (Colour Figure) 434 
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 435 
Figure 7: Quantification of Caspase 3 and NeuN staining of brainstem samples. 436 
 437 
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DIPG Drug Screen  438 
 We conducted a small screen of eight conventionally used chemotherapy agents in three 439 
patient-derived DIPG cell lines. Three agents; Etoposide, Doxorubicin and Mitoxantrone 440 
demonstrated significant toxicity across all three cell lines with correspondingly low IC50 441 
values (mean values of 421nM, 49nM and 50nM respectively) (Fig. 8B). Carboplatin, BCNU 442 
and Melphalan also demonstrated toxicity, but were less effective, requiring higher drug 443 
concentrations. In contrast, both Temozolamide and Cisplatin demonstrated little to no toxicity 444 
in these cell lines. Twelve-point dose escalation curves for Doxorubicin and Temozolamide 445 
can be seen in Figure. 8C.  446 
 447 
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 448 
Figure 8: DIPG Drug Screen. (Colour Figure) 449 
 450 
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BBB disruption using MRgFUS enhances brainstem Doxorubicin uptake  451 
 Following its in vitro efficacy and with poor BBB permeability, Doxorubicin was 452 
selected as the chemotherapeutic agent with which to assess brainstem uptake when combined 453 
with focused ultrasound treatment (Fig. 9). The poor BBB permeability of Doxorubicin was 454 
confirmed in mLFH UDQGRPLVHG WR WKH ³QR LQWHUYHQWLRQ´ JURXS ZKR UHFHLYHG D PJNJ455 
intravenous dose of Doxorubicin and who were subsequently found to have a mean brainstem 456 
value of 7.6ng/g at two hours. Similarly, low values of 18.7 ng/g and 12.31 ng/g were recorded 457 
in control groups receiving intravenous doxorubicin with either focused ultrasound energy 458 
alone (MRgFUS) or PBs alone. Successful BBB opening with MRgFUS and PB in 459 
combination with IV doxorubicin however, resulted in a significantly higher brainstem 460 
doxorubicin level of 431.5 ng/g. This is more than a 50-fold increase FRPSDUHG WR WKH³QR461 
LQWHUYHQWLRQ´ cohort and corresponds to a doxorubicin concentration of 824.2 nM (using a brain 462 
density of 1.04 g/mL [37]). This far exceeds the mean IC50 value of 49 nM of Doxorubicin 463 
recorded in our cell lines.  464 
  Furthermore, MRgFUS + PB + Doxorubicin treated mice showed significantly higher 465 
uptake in the brainstem alone as compared to the cerebrum and cerebellum (p<0.001). This is 466 
attributed to the focal disruption of the BBB in the brainstem using MR image guidance.  467 
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468 
Figure 9: Brain Doxorubicin Distribution. (Colour Figure) 469 
 470 
Discussion: 471 
In this study, we have demonstrated effective BBB disruption in the rodent brainstem 472 
without evidence of tissue injury or functional motor deficit. By using a 4-point sonication grid 473 
in each half of the pons, we were able to achieve diffuse BBB opening in the region, confirmed 474 
by both gadolinium contrast enhancement on T1 weighted imaging and Evans Blue staining of 475 
the tissue.  Following BBB disruption, there were no statistically significant alterations in 476 
critical cardiorespiratory vital signs.  In addition, evaluation of motor pathways and cerebellar 477 
function revealed no decline in function as measured by retained grip strength and rotarod 478 
performance.  Histological analysis of the sonicated regions of the brainstem at both early (4 479 
hours) and late (14 day) time points revealed preserved brainstem architecture and neuronal 480 
numbers without activation of caspase 3 activity. BBB disruption and the administration of the 481 
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chemotherapeutic agent, cisplatin (1.5 mg/kg), was well tolerated without evidence of 482 
physiological brainstem dysfunction.  483 
Further to this, we conducted a drug screen of existing chemotherapy agents which 484 
identified doxorubicin as an effective agent against patient derived DIPG cell lines. 485 
Doxorubicin is known to have poor BBB permeability [38,39] but when combined with 486 
MRgFUS BBB disruption, we were able to show highly effective passage of the drug into the 487 
brainstem. Importantly, the concentration reached in brainstem tissue far exceeded the in vitro 488 
IC50   concentration. The targeted brainstem BBB penetration also resulted in focally enhanced 489 
doxorubicin uptake to the region with limited uptake in other brain regions. Taken together, 490 
our data suggest that MRgFUS can be used to safely target the pons in an experimental model 491 
system and can significantly enhance drug delivery to the region.  This technique may be a 492 
novel and exciting strategy to treat brainstem-specific disorders, such as DIPG.  493 
To date, all chemotherapy trials for DIPG have failed to show improvements in overall 494 
survival.  While treatment failures may relate to the selection of non-targeted drugs for DIPG 495 
or intrinsic tumour cell resistance mechanisms, another reason for failures may be the difficulty 496 
associated with achieving sufficient intra-tumoral doses within the brainstem [40]. The 497 
eloquent location of tumour in the brainstem and preservation of the BBB favour methods of 498 
drug delivery that are both non-invasive and low risk. Although efforts should be made to 499 
improve our understanding of the chemosensitivity of DIPG tumour cells, focal disruption of 500 
the BBB in a transient manner would ensure adequate delivery of appropriately selected drugs.  501 
As has been demonstrated in previous studies in the supratentorial compartment in human 502 
trials, MRgFUS allows for non-invasive, focal, reversible and repetitive BBB disruption [41]. 503 
Convection enhanced delivery (CED) is another technique that has been employed to 504 
improve the delivery of chemotherapeutics to the brainstem (see NCT01502917).  The 505 
technique is currently not clinically approved but promising recent developments in the field 506 
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include the successful completion of a phase 1 trial in patients with DIPG [42] and FDA 507 
approval of a multi-port catheter. However, no drugs are currently approved for direct delivery 508 
into the brain parenchyma. CED is invasive, requiring the insertion of stereotactically guided 509 
catheters directly into the brainstem. As described, CED has some limitations:  Only small 510 
volumes (< 3 mls) can be administrated safely; and only low infusion rates are tolerated [43].  511 
In addition, with CED, drug reflux along the proximal catheter [44] and the limited 512 
extracellular space in the brainstem [43] hinder drug distribution, necessitating the use of 513 
multiple catheters [45]. As such, currently described methods of CED are best suited to short 514 
term drug delivery [44]. 515 
There were some limitations to MRgFUS disruption of the BBB in the brainstem in our 516 
study.  In the rat, the depth of MRgFUS targeting is somewhat challenging due to the small 517 
size and shallow configuration of the cranial vault.  As a result, the centre point of the MRgFUS 518 
target is set more posteriorly towards the cerebellum to minimize reflections of the ultrasound 519 
beam from the skull base. Such reflections can considerably increase the acoustic intensity and 520 
cause harm [46]. The use of a more posteriorly placed FUS target may help to explain the 521 
DFFXPXODWLRQRI VRPH(YDQ¶VEOXHG\H LQ WKHFHUHEHOOXPUHODWLYH WR WKHEUDLQVWHP LQFURVV522 
section.  In mice, this also likely explains the increase in doxorubicin detected in the cerebellum 523 
LQ WKH ³05J)86 P%´ JURXS DOWKRXJK WKLV ZDV QRW D VWDWLVWLFDOO\ VLJQLILFDQW LQFUHDVH In 524 
addition, we used a single FUS transducer in our rodent model.  The use of a single transducer 525 
limits the specificity of the targeted focal area resulting in an ellipsoid shaped region of 526 
coverage [47].  The geometry of the human brain permits the use of multiple transducers which 527 
improve the ability to achieve discrete in-depth focusing. The clinical transducer is also better 528 
able to reduce the distortion of the ultrasound wave from variations in thickness of the skull 529 
[48]. Nonetheless, we were able to demonstrate MR confirmation of BBB disruption in the rat 530 
brainstem following administration of Gadolinium using our technique. Evans Blue 531 
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distribution in brainstem cross sections also clearly depicts that despite the aforementioned 532 
limitations, diffuse dye uptake was seen throughout the brainstem at the level of the pons.  It 533 
is anticipated that even greater specificity of targeting of the pons will be possible with the use 534 
of MRgFUS in patients with DIPG where such anatomical constraints of the skull base are not 535 
so problematic.  536 
We also used cisplatin with the MRgFUS technique in our study to confirm that the 537 
delivery of a chemotherapeutic agent through the BBB and into the brainstem, did not cause 538 
harm. This was confirmed as UDWVLQWKH³MRg)86ȝ%&LV´JURXS did not demonstrate 539 
impaired function or tissue damage.  540 
Cisplatin was chosen for use in our initial rat studies as it is a chemotherapy agent 541 
commonly used as part of combination chemotherapy regimens in the pediatric population. 542 
However, following its limited efficacy in our DIPG cell lines, doxorubicin was chosen for use 543 
in our mouse studies. In addition to its in vitro efficacy and poor BBB permeability, its 544 
pharmacokinetic profile has previously been studied in combination with MRgFUS mediated 545 
BBB disruption and the optimal delivery method to achieve high tissue penetrance whilst 546 
minimising toxicity has been determined [49]. 547 
 Interestingly, in our study, both rat rotarod performance and grip strength were 548 
modestly improved after MRgFUS treatment of the brainstem.  We attribute this improvement 549 
to enhanced performance by the rats from repeated measures as the same operator performed 550 
all measures pre- and post-procedure. This is a documented finding in the literature described 551 
as long-term improvement and is a more probable explanation than the PB or MRgFUS 552 
resulting in brain changes that would enhance their performance [50]. We used a single 553 
operator so as to reduce the likelihood of variations attributed to technique.  554 
 Monitoring of cardiorespiratory parameters was undertaken for several minutes 555 
following MRgFUS and there is the potential that delayed cardiorespiratory effects arose. 556 
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However, all of our rats reached the 14 day time point for histological analysis post treatment 557 
without any behavioural evidence of distress.  558 
 The ȝ%  dose used in our study was twice that of the maximum clinical dose. However, 559 
in clinical translation, more focal locations could be treated following a single bolus by 560 
scanning the ultrasound focus faster than is achievable with the small animal platform used in 561 
this study. Alternatively, a lower ȝ% dose per injection could be used to allow more sonications 562 
within the allowable total dose [51]. Thus in practice, treatments could be performed without 563 
exceeding the maximum clinical dose. 564 
 Although we propose the use of MRgFUS as a repeatable therapy, we have not 565 
demonstrated the safety of repeated treatments in this study. However, repeated focused 566 
ultrasound treatment of the visual pathways has been previously performed in rhesus macaques 567 
and did not result in either histological damage, behavioural change or the ability of the animals 568 
to perform complex visual tasks [46]. Kovacs et al. however, have described sterile 569 
inflammation arising in the brain parenchyma of rodents treated with MRgFUS [52]. We 570 
attribute this to the group¶s use of a single, fixed ultrasound pressure as well as a significantly 571 
KLJKHU ȝ% GRVH with both factors having been shown to result in tissue injury [30]. In 572 
particular, our utilisation of a hydrophone receptor enables the detection of ultra and 573 
subharmonic emissions indicating stable microbubble cavitation and the automated selection 574 
of a sonication pressure previously validated to achieve consistent BBB opening without tissue 575 
damage [30]. Indeed, more recently, McMahon et al. have conducted a study directly 576 
comparing these parameters. They were able to demonstrate contrasting differences in the 577 
degree of inflammatory response and tissue damage consequent to the differing parameters 578 
[53].  579 
 Following our demonstration of the feasibility of MRgFUS BBB disruption in the 580 
rodent brainstem, we have successfully quantified the degree of enhanced drug uptake in the 581 
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region. The high doxorubicin concentration recorded in the brainstem at two hours is 582 
considerable given both the short plasma and tissue half-life of unencapsulated doxorubicin 583 
(5.3 minutes and between 9-23 minutes respectively) [54]. This enhanced drug uptake in the 584 
region of MRgFUS and doxorubicin treated tissue has been shown to persist at 24 hours in a 585 
supratentorial high grade tumour model [55]. Rather uniquely, MRgFUS enables focal BBB 586 
opening with our study demonstrating significantly enhanced doxorubicin uptake in the 587 
brainstem alone as compared to all other brain regions. Although we have demonstrated the 588 
ability to reach brainstem concentrations that exceed our in vitro IC50 concentration, we are 589 
aware that this may not confer a meaningful therapeutic response and this will be the subject 590 
of further work validating the use of MRgFUS in DIPG mouse models. We do however feel 591 
that the ability to achieve such a concentration confers significant promise in a disease process 592 
in which the BBB is a significant barrier to drug delivery.   593 
 In conclusion, in this study we have demonstrated the pre-clinical feasibility of 594 
brainstem BBB disruption using MRgFUS.  We have also demonstrated the potential for 595 
increased and focal drug delivery to the brainstem. Future studies include the scaling up of this 596 
technique in larger animal systems in addition to testing the pre-clinical efficacy of selected 597 
chemotherapeutics in orthotopic patient-derived xenograft or genetically engineered models of 598 
DIPG.   Now that the main molecular genetic drivers of DIPG are known  [7-9,11-14] there is 599 
also a need for rational targeting of these tumours with highly specific pathway inhibitors.  It 600 
is our hope that MRgFUS may play an important role in overcoming the BBB and providing a 601 
safe and reliable drug delivery strategy for the future treatment of DIPG.  602 
 603 
 604 
 605 
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Figure legends: 821 
Figure 1: A. Brainstem sonication schema used in Sprague Dawley rats. MRgFUS was 822 
delivered to a region comprising of a four-point overlapping grid in each half of the pons. B. 823 
Contrast enhanced T1-weighted MR imaging of BBB opening in rats. Axial and sagittal 824 
views of MR imaging performed pre- and post-FUS delivery to the rodent brainstem. Rats who 825 
ZHUH WUHDWHG ZLWK PLFUREXEEOHV RQO\ ȝ% RU MRgFUS only did not demonstrate contrast 826 
enhancement within the brainstem on post procedure imaging. Animals that received MRgFUS 827 
and microbubbles (MRg)86ȝ%GLGVKRZEUDLQVWHPHQKDQFHPHQWWKHUHE\FRQILUPLQJ%%%828 
opening (circles and arrows). The administration of the chemotherapy agent cisplatin (1.5 829 
mg/kg) in addition to the focused ultrasound and microbubbles (MRg)86ȝ%&LVGLGQRW830 
affect the ability to achieve BBB opening and contrast enhancement within the brainstem was 831 
still seen (circles and arrows).  832 
 833 
Figure 2: Evans Blue staining of rodent brainstem confirming BBB opening. Rats were 834 
WUHDWHGZLWKHLWKHUPLFUREXEEOHVRQO\ȝ%MRgFUS or both (MRg)86ȝ%Control ³(YDQV835 
%OXH´rats received no intervention. Following treatment, 4% Evans Blue was administered 836 
intravenously. Animals were then perfused (4% PFA) and brainstem specimens were extracted, 837 
sectioned and imaged. Blue staining was observed on the anterior aspect of the brainstem and 838 
on cross-section of animals in the (MRg)86  ȝ% JURXS RQO\ WKHUHE\ FRQILUPLQJ %%%839 
permeability in the region. 7KLV ZDV QRW WUXH IRU WKH ³ȝ%´, ³05J)86´ DQG ³Evans Blue´840 
treated animals.  841 
 842 
Figure 3: Physiological monitoring of heart and respiratory rate. The MouseOx rodent 843 
monitoring system was used to monitor the heart rate (in red) and respiratory rate (in blue) of 844 
rats during focused ultrasound delivery to the brainstem. Rats were randomised to one of four 845 
Alli et. al Focused Ultrasound Brainstem Drug Delivery 
treatment groups; A) PLFUREXEEOHV RQO\ ȝ% B) focused ultrasound only (MRgFUS), C) 846 
focused ultrasound and microbubbles (MRg)86ȝ%ZLWKD ILQDOJURXSFRQVLVWLQJRI WKH847 
latter in conjunction with intravenous Cisplatin delivery (MRgFUS  ȝ%  &LV (D). 848 
Monitoring was initiated four minutes prior to sonication and continued for four minutes after. 849 
The brainstem was treated in two halves - right and left (pink bars) with re-administration of 850 
microbubbles between treatments due to their short half-life. No significant fluctuations or 851 
abrupt cessation of either parameter was noted during treatment indicating preservation of the 852 
brainstem cardiorespiratory control centres.  853 
 854 
Figure 4: Comparison of mean heart rate and respiratory rate recordings of rats 855 
before, during and after the specified procedures. The MouseOx rodent monitoring 856 
system was used to monitor the heart rate and respiratory rate of rats during focused ultrasound 857 
delivery to the brainstem. Rats were randomised to one of four treatment groups; A) 858 
PLFUREXEEOHVRQO\ȝ%B) focused ultrasound only (MRgFUS), C) focused ultrasound and 859 
PLFUREXEEOHV05J)86ȝ%ZLWKDILQDOJURXSFRQVLVWLQJRIWKHODWWHULQFRQMXQFWLRQZLWK860 
LQWUDYHQRXV &LVSODWLQ GHOLYHU\ 05J)86  ȝ%  &LV (D). Monitoring was initiated four 861 
PLQXWHV ³EHIRUH´ WKH VRQLFDWLRQ ILOOHG VKDSHV continued ³GXULQJ´ VRQLFDWLRQ KDOI-filled 862 
shapes) and continued for four minutes ³after´ completion of the sonication (empty shapes). 863 
The mean recording for each rat within each treatment group is plotted. The mean and standard 864 
deviation of each group is represented by horizontal lines.  No statistically significant 865 
difference in KHDUWDQGUHVSLUDWRU\UDWHZHUHQRWHG³GXULQJ´DQG³DIWHU´DQ\RIWKHLQterventions 866 
when compared to EDVHOLQH³EHIRUH´UHFRUGLQJV(Two way multivariate mixed model ANOVA, 867 
p>0.05).  868 
 869 
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Figure 5: Comparison of rotarod and grip strength performance pre-and post-procedure. 870 
Rats were tested one week pre (filled shapes) and one week post (empty shapes) intervention 871 
ZLWKHLWKHUPLFUREXEEOHVDORQHȝ%IRFXVHGXOWUDVRXQGDORQHMRgFUS), focused ultrasound 872 
and microbubbles (MRg)86  ȝ% RU IRFXVHG XOWUDVRXQG ZLWK PLFUREXEEOHV DQG FLVSODWLQ873 
(MRg)86ȝ%&LVNo difference in rotarod performance (A) or grip strength (B) was 874 
identified when comparing treatment groups ZD\PL[HG0$129$ZLWK7XNH\¶VSRVWKRF875 
test, * p<0.05 for rotarod, ** p<0.001 for grip strength). A significant improvement in 876 
performance was noted in both rotarod and grip strength pre-and post-procedure. 877 
 878 
Figure 6: Hematoxylin and eosin (H&E) staining of brainstem sections. Following focused 879 
ultrasound delivery, brainstem samples were retrieved at early (4 hours) and late (14 days) post 880 
intervention. (A) Schematic demonstrating that three regions of the brainstem were sectioned 881 
and analysed. (B) 7UHDWHGVDPSOHV³MRg)86ȝ%´ZHUHFRPSDUHGWR³XQWUHDWHG´FRQWUROV882 
No evidence of tissue damage in the form of haemorrhage or vacuolation was seen at either the 883 
early or late time points.  884 
 885 
Figure 7: Quantification of Caspase 3 and NeuN staining of brainstem samples. 886 
Histological analysis of brainstem samples was conducted at early (4 hours) and late (14 day) 887 
time points. Three levels of the brainstem were assessed for (A) Caspase 3 staining as a marker 888 
of apoptosis and (B) NeuN staining of neuronal nuclei for quantification. No significant 889 
difference in the percentage area of caspase 3 staining or neuronal number was identified across 890 
all groups at either time point (Three-ZD\0$129$ZLWK7XNH\¶VSRVWKRFWHVW 891 
 892 
Figure 8: DIPG Drug Screen. A drug screen consisting of eight conventional 893 
chemotherapeutic agents was conducted in three patient derived DIPG cell lines (SU-DIPG IV, 894 
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SU-DIPG XIII and SU-DIPG XVII). (A) Dose ranges for each drug tested are outlined and 895 
were obtained from previously published IC50 data in the literature. (B) A heat map was 896 
generated from twelve-point dose escalation curves to demonstrate cell viability at escalating 897 
drug concentrations (left to right). (C) Dose escalation curves for Doxorubicin and 898 
Temozolamide are highlighted to demonstrate the differing efficacy of the two agents in our 899 
cell lines.  900 
Figure 9: Brain Doxorubicin Distribution. NOD/SCID/GAMMA mice were injected with 901 
5mg/kg intravenous Doxorubicin with either no intervention, microbubbles alone (PB), 902 
focused ultrasound alone (MRgFUS) or both microbubbles and focused ultrasound (MRgFUS 903 
+ PB). Focused ultrasound, when used, was targeted at the brainstem specifically. Greatest 904 
Doxorubicin uptake was seen in the brainstem of the MRgFUS + PB treated group as compared 905 
to all other groups and brain regions (two- way mixed ANOVA, ** p < 0.01, *** p < 0.001).  906 
 907 
Supplementary Figures: 908 
Supplementary Figure 1:  Caspase 3 stained sections at early and late time points. 909 
Following treatment with focused ultrasound and intravenously administered microbubbles, 910 
rodents were perfused and brainstems retrieved at 4-hour (MRg)86ȝ%($5/<and 14 911 
day (MRg)86ȝ%/$7( time points. Brainstems were sectioned at three levels and stained 912 
for Caspase 3 activity as a marker of apoptosis. Sections were compared to Caspase 3 stained 913 
sections of untreated controls (Untreated). No difference in the degree of Caspase 3 staining 914 
was noted.  915 
Supplementary Figure 2: NeuN stained sections at early and late time points. Following 916 
treatment with focused ultrasound and intravenously administered microbubbles, rodents were 917 
perfused and brainstems retrieved at 4-hour (MRg)86ȝ%($5/<and 14 day (MRgFUS 918 
ȝ%/$7( time points. Brainstems were sectioned at three levels and stained for NeuN to 919 
Alli et. al Focused Ultrasound Brainstem Drug Delivery 
quantify neuronal number. Sections were compared to Caspase 3 stained sections of untreated 920 
controls (Untreated). No difference in the number or morphology of neurons was identified.  921 
Supplementary Figure 3: (A) Brainstem sonication schema used in NSG Mice. MRgFUS 922 
was delivered to a region comprising of a four-point overlapping grid in the centre of the pons. 923 
B. Contrast enhanced T1-weighted MR imaging of BBB opening in mice. Axial and sagittal 924 
views of MR imaging performed pre- and post-FUS delivery to the murine brainstem. Mice 925 
who UHFHLYHG³QRLQWHUYHQWLRQ´RUwere treated with PLFUREXEEOHVRQO\ȝ%RUMRgFUS only 926 
(MRgFUS) did not demonstrate contrast enhancement within the brainstem on post procedure 927 
imaging. Animals that received MRgFUS and microbubbles (MRg)86  ȝ% GLG VKRZ928 
brainstem enhancement, thereby confirming BBB opening (circle and arrow). 929 
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SUPPLEMENTARY DATA (at reviewers request): 946 
 947 
 948 
Supplementary Figure 1:  Caspase 3 stained sections at early and late time points. 949 
Following treatment with focused ultrasound and intravenously administered microbubbles, 950 
rodents were perfused and brainstems retrieved at 4-hour (MRg)86ȝ%($5/<and 14 951 
day (MRg)86ȝ%/$7( time points. Brainstems were sectioned at three levels and stained 952 
for Caspase 3 activity as a marker of apoptosis. Sections were compared to Caspase 3 stained 953 
sections of untreated controls (Untreated). No difference in the degree of Caspase 3 staining 954 
was noted.  955 
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 956 
Supplementary Figure 2: NeuN stained sections at early and late time points. Following 957 
treatment with focused ultrasound and intravenously administered microbubbles, rodents were 958 
perfused and brainstems retrieved at 4-hour (MRg)86ȝ%($5/<and 14 day (MRgFUS 959 
ȝ%/$7( time points. Brainstems were sectioned at three levels and stained for NeuN to 960 
quantify neuronal number. Sections were compared to Caspase 3 stained sections of untreated 961 
controls (Untreated). No difference in the number or morphology of neurons was identified.  962 
 963 
 964 
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Supplementary Figure 3: (A) Brainstem sonication schema used in NSG Mice. MRgFUS 965 
was delivered to a region comprising of a four-point overlapping grid in the centre of the pons. 966 
B. Contrast enhanced T1-weighted MR imaging of BBB opening in mice. Axial and sagittal 967 
views of MR imaging performed pre- and post-FUS delivery to the murine brainstem. Mice 968 
who UHFHLYHG³QRLQWHUYHQWLRQ´RUZHUHWUHDWHGZLWKPLFUREXEEOHVRQO\ȝ%RUMRgFUS only 969 
(MRgFUS) did not demonstrate contrast enhancement within the brainstem on post procedure 970 
imaging. Animals that received MRgFUS and microbubbles (MRg)86  ȝ% GLG VKRZ971 
brainstem enhancement, thereby confirming BBB opening (circle and arrow). 972 
 973 
 974 
Supplementary Figure 4: Evans Blue staining of rodent brainstem confirming BBB opening 975 
(all rats).  Rats ZHUHWUHDWHGZLWKHLWKHUPLFUREXEEOHVRQO\ȝ%MRgFUS or both (MRgFUS 976 
 ȝ% Control rats received no intervention. Following treatment, 4% Evans Blue was 977 
administered intravenously. Animals were then perfused (4% PFA) and brainstem specimens 978 
were extracted, sectioned and imaged. Blue staining was observed on the anterior aspect of the 979 
brainstem and on cross-section of animals in the (MRg)86  ȝ% JURXS RQO\ WKHUHE\980 
confirming BBB permeability in the region. 7KLVZDVQRWWUXHIRUWKH³ȝ%´³05J)86´DQG981 
³FRQWURO´WUHDWHGDQLPDOV 982 
 Please NB: Due to the large file size, this figure could not be embedded into this word 983 
document and has been uploaded to the submission website separately.  984 
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